Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 6/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2522571 | 0.98 | THRB (0.49) | THRBTGFBR1MAPK14CSNK1ECSNK1D | |
| SCHEMBL2522830 | 0.94 | THRB (0.53) | THRBTGFBR1MAPK14CSNK1ECSNK1D | |
| SCHEMBL2524316 | 0.83 | PTGS2 (0.45) | THRBTGFBR1MAPK14MEN1KMT2A | |
| SCHEMBL16708797 | 0.82 | CSNK1D (0.42) | THRBTGFBR1CSNK1ECSNK1DKDM4E | |
| SCHEMBL17382369 | 0.81 | THRB (0.49) | THRBTGFBR1MAPK14CSNK1ECSNK1D | |
| SCHEMBL17373680 | 0.81 | THRB (0.49) | THRBTGFBR1MAPK14CSNK1ECSNK1D | |
| SCHEMBL2524961 | 0.79 | PTGS2 (0.44) | THRBTGFBR1MAPK14 | |
| SCHEMBL2526796 | 0.79 | TGFBR1 (0.53) | THRBTGFBR1MAPK14KDM4E | |
| SCHEMBL2521875 | 0.78 | THRB (0.43) | THRBTGFBR1MAPK14KDM4E | |
| SCHEMBL2522456 | 0.78 | THRB (0.44) | THRBTGFBR1MAPK14MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2556073-B1 | BICYCLIC PYRIDINYL PYRAZOLES | BAYER IP GMBH (DE) | 2014-07-23 | — | — | EP | disclosed |
| US-8507472-B2 | Bicyclic pyridinylpyrazoles | BAYER CROPSCIENCE AG (DE) | 2013-08-13 | — | — | US | disclosed |
| EP-2556073-A1 | BICYCLIC PYRIMIDINYL PYRAZOLES | Bayer Intellectual Property GmbH (DE) | 2013-02-13 | — | — | EP | disclosed |
| WO-2011124539-A1 | BICYCLIC PYRIMIDINYL PYRAZOLES | BAYER CROPSCIENCE AG (DE) | 2011-10-13 | — | — | WO | disclosed |
| US-20110251178-A1 | Bicyclic Pyridinylpyrazoles | BAYER CROPSCIENCE AG (DE) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251178-A1 | Bicyclic Pyridinylpyrazoles | PLPBP, PNPO, PIR | THRB 3803/4885TGFBR1 2921/4885MAPK14 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.